ABI
MCK icon

Adamant Biomedical Investments’s McKesson MCK Stock Holding History

Adamant Biomedical Investments’s Portfolio MCK Stock Details MCK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$8.51M Hold
41,000
– – 2.03% 13
2014
Q3 		$7.98M Buy
+41,000
New +$7.89M 1.99% 14

Other funds holding MCK

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Winslow Capital Management
Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Adamant Biomedical Investments's MCK Position: Q4 2014 in Review

Adamant Biomedical Investments held its McKesson (MCK) position steady in Q4 2014 at 41,000 shares worth $8.51M. The position accounts for 2.03% of the portfolio, ranked #13.

Adamant Biomedical Investments first reported a position in MCK in Q3 2014 and has held it in 2 quarters since. 889 funds tracked by Wall St. Rank hold MCK as of Q4 2014.

  • Adamant Biomedical Investments held 41,000 shares of McKesson worth $8.51M as of Q4 2014.
  • Adamant Biomedical Investments left its McKesson share count unchanged in Q4 2014.
  • McKesson made up 2.03% of Adamant Biomedical Investments's portfolio in Q4 2014, its #13 holding.
  • Adamant Biomedical Investments first reported a position in McKesson in Q3 2014 and has held it in 2 quarters since.
  • 889 funds tracked by Wall St. Rank held McKesson as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.